Article
Oncology
Lily Chen, Bhavani S. Gannavarapu, Neil B. Desai, Michael R. Folkert, Michael Dohopolski, Ang Gao, Chul Ahn, Jeffrey Cadeddu, Aditya Bagrodia, Solomon Woldu, Ganesh V. Raj, Claus Roehrborn, Yair Lotan, Robert D. Timmerman, Aurelie Garant, Raquibul Hannan
Summary: This study analyzed the use of stereotactic ablative radiation (SAbR) at a dose of 45 Gy in 5 fractions for prostate cancer. The results showed promising safety profiles, but further prospective studies are needed to establish this dose regimen as standard of care.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Raquibul Hannan, Michael Christensen, Alana Christie, Aurelie Garant, Ivan Pedrosa, Liliana Robles, Samantha Mannala, Chiachien Wang, Hans Hammers, Waddah Arafat, Kevin Courtney, Isaac A. Bowman, David Sher, Chul Ahn, Suzanne Cole, Hak Choy, Robert Timmerman, James Brugarolas
Summary: This study evaluated the feasibility of SAbR for patients with systemic therapy-naive oligometastatic RCC and found that SAbR can provide long-term disease control while preserving quality of life for patients.
EUROPEAN UROLOGY ONCOLOGY
(2022)
Review
Oncology
Andrew B. Barbour, Simon Kirste, Anca-Liga Grosu, Shankar Siva, Alexander V. Louie, Hiroshi Onishi, Anand Swaminath, Bin S. Teh, Sarah P. Psutka, Emily S. Weg, Jonathan J. J. Chen, Jing Zeng, John L. Gore, Evan Hall, Jay J. J. Liao, Rohann J. M. Correa, Simon S. Lo
Summary: Patients with localized renal cell carcinoma often have medical comorbidities limiting their surgical candidacy, thus necessitating less invasive treatment options. Stereotactic ablative radiotherapy has emerged as a safe and effective management option with a growing body of evidence supporting its use. This article discusses recent advances in the use of stereotactic ablation radiotherapy for localized renal cell carcinoma, while guiding providers on practical points for patient selection and clinical application.
Review
Oncology
Megan E. Daly
Summary: Stereotactic ablative radiotherapy (SABR) is the standard treatment for medically inoperable, early-stage non-small-cell lung cancer. However, regional and distant failures remain a challenge, especially in larger and more biologically aggressive tumors. Use of cytotoxic chemotherapy is limited in this patient population, prompting the investigation of alternative systemic therapy options with fewer side effects, such as immune checkpoint inhibitors.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Bin Wang, Yang Dong, Xuyao Yu, Fengtong Li, Jingsheng Wang, Huaming Chen, Zeqian Niu, Yongchun Song, Zhiyong Yuan, Zhen Tao
Summary: SBRT treatment at a dose of 56 Gy/6-8f is beneficial for UCLC patients, and smaller PTV is associated with better outcomes.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Annaig Bertho, Morgane Dos Santos, Sarah Braga-Cohen, Valerie Buard, Vincent Paget, Olivier Guipaud, Georges Tarlet, Fabien Milliat, Agnes Francois
Summary: By utilizing three-fraction schedules delivered over a period of 1 week with doses per fraction of 20, 28, 40, and 50 Gy, only 3 x 40 Gy or 3 x 50 Gy generated focal lung fibrosis after 6 months. The study suggests that a fractionation schedule using an arc-therapy-delivered three fractions/1 week regimen with 3 x 3 mm beam requires 40 Gy per fraction for lung fibrosis to develop within 6 months.
FRONTIERS IN MEDICINE
(2021)
Review
Oncology
Eric J. Lehrer, Raj Singh, Ming Wang, Vernon M. Chinchilli, Daniel M. Trifiletti, Piet Ost, Shankar Siva, Mao-bin Meng, Leila Tchelebi, Nicholas G. Zaorsky
Summary: The meta-analysis shows that stereotactic ablative radiotherapy is relatively safe and clinically beneficial in patients with oligometastatic cancer, with low rates of toxic effects and acceptable survival rates. Further research is needed to validate these findings.
Article
Oncology
Raquibul Hannan, Michael Christensen, Hans Hammers, Alana Christie, Brendan Paulman, Dandan Lin, Aurelie Garant, Waddah Arafat, Kevin Courtney, Isaac Bowman, Suzanne Cole, David Sher, Chul Ahn, Hak Choy, Robert Timmerman, James Brugarolas
Summary: SAbR treatment can extend the duration of ongoing systemic therapy for mRCC patients with limited progression without compromising quality of life.
EUROPEAN UROLOGY ONCOLOGY
(2022)
Article
Oncology
Mihailo Miljanic, Chika Nwachukwu, Assal Rahimi
Summary: This case series and literature review suggest that definitive ablative radiation therapy may serve as a safe and effective treatment option for non-operable patients with early stage breast cancer. The observed durable treatment responses and minimal toxicity support the potential of this approach.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Mihailo Miljanic, Chika Nwachukwu, Assal Rahimi
Summary: This case series and literature review investigate the efficacy and safety of definitive ablative radiation therapy for non-operable patients with early stage breast cancer. The two cases presented demonstrate the potential of this approach to achieve durable responses.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Michael F. Gensheimer, Harriet Gee, Hiroki Shirato, Hiroshi Taguchi, John M. Snyder, Alexander L. Chin, Lucas K. Vitzthum, Peter G. Maxim, Heather A. Wakelee, Joel Neal, Millie Das, Daniel T. Chang, Elizabeth Kidd, Steven L. Hancock, David B. Shultz, Kathleen C. Horst, Quynh-Thu Le, Samantha Wong, Eleanor Brown, Ngan Nguyen, Rachel Liang, Billy W. Loo, Maximilian Diehn
Summary: Stereotactic ablative radiotherapy (SABR) can be individualized based on tumor size, location, and histological characteristics to achieve excellent local control for lung tumors. This nonrandomized controlled trial suggests that individualized SABR may allow minimization of treatment dose and reduce toxic effects.
Article
Oncology
Henan Zhang, Jacob J. Orme, Feven Abraha, B. J. Stish, Val J. Lowe, Fabrice Lucien, Erik J. Tryggestad, Michael S. Bold, Lance C. Pagliaro, C. Richard Choo, Debra H. Brinkmann, Matthew J. Iott, Brian J. Davis, J. Fernando Quevedo, William S. Harmsen, Brian A. Costello, Geoffrey B. Johnson, Mark A. Nathan, Kenneth R. Olivier, Thomas M. Pisansky, Eugene D. Kwon, Haidong Dong, Sean S. Park
Summary: The study showed that high levels of tumor-reactive T cells and effector memory T cells were associated with better outcomes in oligometastatic CRPC patients treated with SABR. This supports the incorporation of immune-based markers in the design of future randomized trials in this patient population.
CLINICAL CANCER RESEARCH
(2021)
Review
Oncology
Zarique Z. Akanda, Paul J. Neeson, Thomas John, Stephen Barnett, Gerard G. Hanna, Alistair Miller, Ross Jennens, Shankar Siva
Summary: ICIs have improved overall survival in m-NSCLC, but resistance is a challenge. Combining ICIs with other treatments to modulate the TME and sensitize tumours is promising. Further investigation is needed for optimal combinations, dosing, and sequencing of ICI + SABR in m-NSCLC.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Oncology
Robert Olson, Will Jiang, Mitchell Liu, Alanah Bergman, Devin Schellenberg, Benjamin Mou, Abraham Alexander, Hannah Carolan, Fred Hsu, Stacy Miller, Siavash Atrchian, Elisa Chan, Clement Ho, Islam Mohamed, Angela Lin, Tanya Berrang, Andrew Bang, Nick Chng, Quinn Matthews, Sarah Baker, Vicky Huang, Ante Mestrovic, Derek Hyde, Chad Lund, Howard Pai, Boris Valev, Shilo Lefresene, Scott Tyldesley
Summary: This study confirms that the incidence of high-grade toxic effects in the large cohort of patients receiving SABR for oligometastases is less than 5%. The lower rates of toxic effects compared to previous studies may support further enrollment in randomized phase 3 clinical trials.
Article
Oncology
Evert Jan Van Limbergen, Ann Hoeben, Relinde I. Y. Lieverse, Ruud Houben, Chantal Overhof, Alida Postma, Jaap Zindler, Frans Verhelst, Ludwig J. Dubois, Dirk De Ruysscher, Esther G. C. Troost, Philippe Lambin
Summary: The study evaluated the safety and tolerability of L19-IL2 after SBRT, showing good tolerance at the 15 million IU dose level but dose-limiting toxicity at the recommended dose level. Two long-term progression-free responders were documented, and the therapeutic efficacy is being further evaluated in a multicentric phase 2 clinical trial.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Engineering, Biomedical
Mathieu Gaudreault, James Korte, Nicholas Bucknell, Price Jackson, Pitchaya Sakyanun, Lachlan McIntosh, Beverley Woon, James P. Buteau, Michael S. Hofman, Tony Mulcahy, Tomas Kron, Shankar Siva, Nicholas Hardcastle
Summary: This study aims to determine the correlation between PBV determined from DECT and PET in the context of FLA radiotherapy. The results showed a strong correlation between DECT and PET determination of PBV, but there may be some factors that affect the correlation in the posterior region.
PHYSICS IN MEDICINE AND BIOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Colin John Martin, Sebastien Gros, Tomas Kron, Tim J. Wood, Jenia Vassileva, William Small Jr, Ung Ngie Min
Summary: The research provides data on imaging practices in radiotherapy services in different countries. The information will be used to make recommendations for optimizing radiological protection and evaluating additional dosimetry features for cone beam CT facilities in radiotherapy equipment. The findings highlight the need for raising awareness of imaging doses and developing dose quantities displayed on imaging equipment.
APPLIED SCIENCES-BASEL
(2023)
Article
Oncology
D. Berger, S. Van Dyk, L. Beaulieu, T. Major, T. Kron
Summary: This review highlights the emergence of brachytherapy tools and technologies over the past decade. Advances in soft-tissue imaging using magnetic resonance and ultrasound have greatly improved the planning of brachytherapy. Image-guided brachytherapy has led to the development of advanced applicators and the use of 3D printing for precise and reproducible implants. Improved dosimetry algorithms and dose optimization toolkits have enhanced the accuracy and efficiency of brachytherapy treatment planning. Traditional planning strategies remain relevant for validating new technologies. Overall, brachytherapy has evolved to become a high-tech and modern treatment while maintaining accessibility for all.
Article
Oncology
M. Swain, A. Budrukkar, A. Rembielak, T. Kron, J. P. Agarwal
Summary: Brachytherapy plays an irreplaceable role in certain cancers, but there are challenges in its preservation, accessibility, and distribution of care. There is an uneven distribution of brachytherapy facilities globally, especially in low and low-middle income countries. Bridging this gap requires a focus on uniform distribution, improving training, reducing costs, and generating evidence and guidelines.
Editorial Material
Oncology
A. Rembielak, A. Budrukkar, T. Kron
Article
Oncology
Nicholas W. Bucknell, Tomas Kron, Alan Herschtal, Nicholas Hardcastle, Louis Irving, Michael Macmanus, Gerard G. Hanna, Alisha Moore, Andrew Murnane, Shankar Siva, CHISEL coauthors
Summary: The study compares the effects of conventional radiation therapy (CRT) and stereotactic body radiation therapy (SBRT) in patients with inoperable early-stage non-small cell lung cancer. The results show that there is no significant difference in pulmonary function and walking distance between the two groups at 3 and 12 months after treatment.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Nicholas W. Bucknell, Nicholas Hardcastle, Beverley Woon, Lisa Selbie, Mathias Bressel, Keelan Byrne, Jason Callahan, Gerard G. Hanna, Michael S. Hofman, David Ball, Tomas Kron, Shankar Siva
Summary: The study explores the use of 4-dimensional gallium 68 ventilation-perfusion positron emission tomography-computed tomography (Ga-68-4D-V/Q PET/CT) to spare functional lung during radiation therapy. The results demonstrate that FLA significantly reduces the radiation dose to functional lung, leading to positive outcomes in terms of survival rates and quality of life.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Shankar Siva, Pitchaya Sakyanun, Tao Mai, Wenchang Wong, Adeline Lim, Joanna Ludbrook, Catherine Bettington, Angela Rezo, David Pryor, Nicholas Hardcastle, Tomas Kron, Braden Higgs, Hien Le, Marketa Skala, Suki Gill, Thomas Eade, Raef Awad, Giuseppe Sasso, Shalini Vinod, Rebecca Montgomery, David Ball, Mathias Bressel
Summary: This article reports on a randomized clinical trial comparing single- versus multifraction stereotactic ablative body radiotherapy (SABR) in patients with oligometastases to the lung. The study found no differences in safety, efficacy, systemic immunogenicity, or survival between the two treatment arms, with single-fraction SABR selected based on cost-effectiveness. The final updated survival outcome analysis showed no differences in overall survival, disease-free survival, or modified disease-free survival between the two arms.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Peta Lonski, Michael MacManus, Belinda A. Campbell, Greg Wheeler, Elena Ungureanu, Tomas Kron
Summary: This study reported lung doses for 142 TBI patients and found that the use of lung shielding blocks in standing TBI significantly reduced lung doses. On the other hand, patients treated lying down had higher lung doses compared to those treated standing.
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY
(2023)
Article
Oncology
Mathieu Gaudreault, David Chang, Nicholas Hardcastle, Price Jackson, Tomas Kron, Michael S. Hofman, Shankar Siva
Summary: This study explores the feasibility of combining Biology-guided radiotherapy (BgRT) with Lutetium-177 [Lu-177]-PSMA-617 for the treatment of PSMA-negative/FDG-positive metastatic prostate cancer. The conclusion is that this combination therapy is feasible for patients with PSMA/FDG discordant metastases.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Mathieu Gaudreault, David Chang, Nicholas Hardcastle, Lachlan McIntosh, Price Jackson, Tomas Kron, Cristian Udovicich, Michael S. Hofman, Shankar Siva
Summary: This study aims to determine the feasibility of Biology-guided radiotherapy (BgRT) treatment for renal cell carcinoma (RCC). It was found that over 60% of tumors in RCC patients were suitable for BgRT. However, the proximity of PET-avid organs such as the liver or the kidney may affect BgRT delivery.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2023)
Article
Oncology
Nicholas Bucknell, Nicholas Hardcastle, Roshini Gunewardena, Long Nguyen, Jason Callahan, David Ball, Lisa Selbie, Tomas Kron, Guy-Anne Turgeon, Michael S. Hofman, Shankar Siva
Summary: This study assessed the feasibility of using 68Ga-4D-V/Q PET/CT for dynamic imaging of lung function and adapting radiation therapy plans to changes in lung function during mid-treatment. The results showed that mid-treatment adaptation could reduce the dose to functional lung volumes in some NSCLC patients. The role of mid-treatment adaptation requires further investigation.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2023)
Article
Oncology
Jelena Lukovic, Alisha J. Moore, Mark T. Lee, David Willis, Shahida Ahmed, Mohamed Akra, Eszter Hortobagyi, Tomas Kron, Daryl Lim Joon, Amy Liu, John Ryan, Melissa Thomas, Katelyn Wall, Iain Ward, Kirsty L. Wiltshire, Chris J. O'Callaghan, Rebecca K. S. Wong, Jolie G. Ringash, Karin Haustermans, Trevor Leong
Summary: This study aimed to investigate whether adding preoperative chemoradiation therapy could improve the survival rate in gastric cancer patients, and a comprehensive radiation therapy quality assurance program was implemented. The study found that ongoing education is necessary to ensure consistent quality during the entire study period.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Mathieu Gaudreault, David Chang, Tomas Kron, Shankar Siva, Sarat Chander, Nicholas Hardcastle, Adam Yeo
Summary: This study introduces a fully automated method for generating an ordered lattice of vertices and performing dose optimization and calculation in lattice radiation therapy (LRT). The dosimetry associated with different lattice geometries was evaluated and it was found that lattices with specific center-to-center distances had the best scores.
Meeting Abstract
Oncology
S. Siva, M. Bressel, M. Sidhom, S. Sridharan, B. Vanneste, R. Davey, J. Ruben, F. Foroudi, B. G. Higgs, C. Lin, A. Raman, N. Hardcastle, M. Shaw, P. Mancuso, N. Lawrentschuk, S. Wood, N. Brook, T. Kron, J. M. Martin, D. I. Pryor
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)